Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Drugs that Cause Movement Disorders

Most of us learned in our professional training that neuroleptic agents cause movement disorders, or extrapyramidal symptoms (EPS).1 Neuroleptics, the older class of antipsychotic agents, which includes dopamine receptor blocking agents (DRBA), can cause tardive dyskinesia (TD), dystonia, akathisia, and Parkinsonism.

We also learned that newer antipsychotic agents, the so-called second-generation antipsychotics, do not cause EPS. However, dose-related EPS has been associated with olanzapine and risperidone use (> 6 mg/day doses), and there have been two reported cases of aripiprazole-induced EPS.2,3

So which symptoms indicate a drug-induced movement disorder (DIMD)? Patients with DIMDs have difficulty with social functioning, motor-task performance, interpersonal communication, and activities of daily living. They also are less likely to adhere to a medication regimen, making disease relapse and rehospitalization more likely.

Market watch

First-time generics:

  • Dronabinol (generic Marinol);
  • Risperidone (generic Risperdal);
  • Trandolapril (generic Mavik).

New Drugs, Indications, Dosage Forms, and Information

  • Bupivacaine transdermal patch (Eladur) received orphan-drug status for treating pain of post-herpetic neuralgia (PHN). Orphan status gives the manufacturer seven years of marketing exclusivity. This is the same indication that lidocaine patches (Lidoderm) originally received in 1999, although not with orphan-drug status.
  • Dutasteride (Avodart) combined with tamsulosin (Flomax) has been Food and Drug Administration (FDA)-approved for treating symptomatic prostatic hypertrophy.
  • Fluticasone propionate 250 mcg/salmeterol 50 mcg inhalation powder (Advair Diskus 250/50) has been FDA-approved for exacerbation reduction in chronic obstructive pulmonary disease patients with a history of exacerbations.
  • Sumatriptan 85 mg/naproxen sodium 500 mg (Treximet) combination tablets have been FDA-approved for treating acute migraines with or without an aura.
  • Denosumab, a fully humanized monoclonal antibody, is in Phase 3 clinical trials for the treatment of post-menopausal osteoporosis. Its effect on rheumatoid arthritis and cancer-related bone loss is also being studied.

It has a new mechanism of action compared to currently available agents that prevent or treat osteoporosis. It targets RANK Ligand and inhibits early stage osteoclast activity.7 Denosumab also recently met primary and secondary bone mineral density (BMD) study endpoints compared to alendronate. The primary BMD endpoint in the hip was approximately 80% greater for denosumab than alendronate. Denosumab is dosed twice yearly.

Finally, diabetes drugs currently are in the lead for prescription drug spending growth, according to the Medco Annual Drug Trend Report.1 During the past 10 years, lipid-lowering therapies drove this trend. In this most recent report, spending on cholesterol-lowering drugs significantly fell due to the availability of lower priced generics, but still account for 10.8% of all prescription costs.

Spending on diabetes drugs as a whole increased by 12% due to use of higher-cost medications and drug inflation, yet utilization of these drugs increased by only 2.3%. Since diabetes has become an epidemic, more patients are being treated with newer, higher-cost treatments, as well as, two- or three-drug regimens.

Reference

  1. http://medco.mediaroom.com/index.php?s=64

Some DIMDs are worse than others. Neuroleptic-induced TD, for example, is in some cases irreversible and can lead to functional impairment so severe a patient cannot feed himself, speak clearly, or breathe easily. In addition, removal of the offending agent does not always resolve TD.4

Milder forms of neuroleptic-induced TD occur in about 20% of patients. In higher risk groups, such as older patients, milder forms of neuroleptic-induced TD may exceed 50%.

DIMDs often elude diagnosis by clinicians, partially because they look like other medical conditions such as restless legs syndrome, agitation, or drug withdrawal. Clinicians who understand the most likely DIMD culprits and the effect of each can better manage their patients. It’s also crucial for clinicians to pay attention to

  • Drugs that Cause Movement Disorders

    October 1, 2008

  • The Burdens of Comanagement

    October 1, 2008

  • In the Literature

    October 1, 2008

  • Neal R. Axon, MD

    October 1, 2008

  • 1

    SHM Invests in ‘Champions’ and SHM’s Future

    October 1, 2008

  • A Bumpy Bundling Road Ahead

    October 1, 2008

  • The New Intensivists

    October 1, 2008

  • 1

    Certification on Our Minds

    September 2, 2008

  • 1

    The 4-1-1 on NPPs

    September 2, 2008

  • 1

    Left Turns

    September 2, 2008

1 … 886 887 888 889 890 … 967
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences